Eli Lilly and Company (NYSE: LLY) announced it will present results from two Phase 3 studies of Jaypirca (pirtobrutinib) for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE